Scott Gottlieb, who served as US Food and Drug Administration commissioner during the first half of president Trump’s first term, advised the pharmaceutical industry to seek a legislative extension of the user fee program because he sees “nothing good” coming from negotiating new agreements in the “current political environment.”
User Fees: Industry Should Push For Extension Of Current Agreement In Reconciliation Bill, Gottlieb Says
Trump’s former FDA commissioner sees ‘nothing good’ coming from negotiating a new user fee agreement in the ‘current political environment.’
More from AAM
More from Policy & Regulation
• By
Complaints from UK originator association the ABPI over rising payments required by the country’s voluntary scheme for branded medicines pricing have been denounced by the BGMA, which says the differentiated scheme is “delivering precisely as it was intended.”
• By
The FDA generic drugs team’s first public workshop of the second Trump Administration ended with a request that industry amplify the value it finds from public engagement.
• By
Generics Bulletin reviews global regulatory developments across the globe.